SUTRO BIOPHARMA, INC. Deferred Revenue (Non-Current)
SUTRO BIOPHARMA, INC. (STRO) had Deferred Revenue (Non-Current) of $48.80 million as of 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2018-11-14
- 2018-09-30: Deferred Revenue, Noncurrent $48.80M.
- 2017-12-31: Deferred Revenue, Noncurrent $13.16M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2018-09-30 | $48.80M 10-Q · filed 2018-11-14 |
| 2017-12-31 | $13.16M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |